Compare HRMY & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | PRLB |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2020 | 2011 |
| Metric | HRMY | PRLB |
|---|---|---|
| Price | $38.04 | $84.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $48.25 | ★ $95.50 |
| AVG Volume (30 Days) | ★ 750.6K | 194.6K |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 33.33 |
| EPS | ★ 1.84 | 0.71 |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $18.62 | $9.25 |
| Revenue Next Year | $13.23 | $7.56 |
| P/E Ratio | ★ $20.62 | $120.74 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.81 | $45.10 |
| 52 Week High | $43.49 | $99.96 |
| Indicator | HRMY | PRLB |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 39.18 |
| Support Level | $37.48 | $77.11 |
| Resistance Level | $39.35 | $93.00 |
| Average True Range (ATR) | 1.28 | 3.31 |
| MACD | -0.24 | -1.49 |
| Stochastic Oscillator | 50.52 | 4.07 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.